At the time of writing, Ionis Pharmaceuticals Inc [IONS] stock is trading at $70.59, up 0.89%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IONS shares have gain 2.27% over the last week, with a monthly amount glided 11.76%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on October 08, 2025, when JP Morgan upgraded its rating to a Overweight but kept the price target unchanged to $80 for it. Previously, Goldman upgraded its rating to Neutral on September 26, 2025, and kept the price target unchanged to $65. On September 03, 2025, upgrade upgraded it’s rating to Outperform but maintained its price target of $70 on the stock. Morgan Stanley upgraded its rating to a Overweight but stick to its price target of $62 on July 31, 2025. Barclays upgraded its rating to a Overweight but $57 remained the price target by the analyst firm on July 01, 2025. H.C. Wainwright started tracking with a Buy rating for this stock on April 07, 2025, and assigned it a price target of $45. In a note dated March 31, 2025, Redburn Atlantic initiated an Neutral rating and provided a target price of $39 on this stock.
For the past year, the stock price of Ionis Pharmaceuticals Inc fluctuated between $23.95 and $71.87. Currently, Wall Street analysts expect the stock to reach $79.36 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $70.59 at the most recent close of the market. An investor can expect a potential return of 12.42% based on the average IONS price forecast.
Analyzing the IONS fundamentals
According to Ionis Pharmaceuticals Inc [NASDAQ:IONS], the company’s sales were 944.48M for trailing twelve months, which represents an 100.69% jump. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -0.28%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.45 and Total Capital is -0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Ionis Pharmaceuticals Inc [NASDAQ:IONS] has a current ratio of 2.87. In addition, the Quick Ratio stands at 2.86 and the Cash Ratio stands at 0.33. Considering the valuation of this stock, the price to sales ratio is 11.91, the price to book ratio is 17.79.
Transactions by insiders
Recent insider trading involved Swayze Eric, EVP Research, that happened on Oct 06 ’25 when 6849.0 shares were sold. EVP CLO & General Counsel, O’NEIL PATRICK R. completed a deal on Oct 06 ’25 to sell 13441.0 shares. Meanwhile, Chief Executive Officer Monia Brett P sold 437.0 shares on Oct 06 ’25.
